Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (April 2005)
23 slides from Resonance Health's investor presentation, Apr 7, 2005
Slide 1: Commercialising the FerriScan Technology: Investor Update April 2005
resonance health | Commercialising the Ferriscan™ Technology “The Future of Liver Diagnosis” Investor Update April 2005
Slide 2: Commercialising the Ferriscan Technology
Commercialising the Ferriscan™ Technology “The Future of Liver Diagnosis” c * Resonance Health Limited (ASX:RHT) — specialises in technology, focussing initially on the liver. * The Ferriscan™ Technology is a novel, non-invasive liver diagnostic with global applications developed by a multi-discipli
Slide 3: What is the Ferriscan Technology
What is the Ferriscan™ Technology « Asafe, non-invasive and accurate test to measure liver iron conc « Utilises existing MRI equipment, proprietary software and a patented iron “marker” known as “R2” ¢ Provides clinicians around the world with a new and safe diagnostic tool to track liver iron level
Slide 4: Why Test for Iron Overload?
Why Test for lron Overload? * Chronic disorders of iron metabolism are among 16 common genetic diseases (1 in 200 for HHC) * The result is too much iron is absorbed by the digestive system and accumulates in the body (and in its largest organ — the liver) * lron overload has previously been difficul
Slide 5: Diseases Associated With Iron Overload
Diseases Associated With lron Overload * Haemochromatosis — Ahereditary disease in which excessive amounts of iron are absorb stored in the body, particularly the liver. Treatment is typically blood removal. . every week over a iwo year period. Hereditary Haemochromatosis (HHC) is the most common ge
Slide 6: Distribution Map
Distribution Map - lron Overload Disorders 4,000,000 10,000,000 100,000 resonance ih arriieci
Slide 7: Other Direct Applications for the Ferriscan Technology Platform
Other Direct Applications for the Ferriscan™ Technology Platt * Hepatitis C ~ Assessment of liver iron levels to ensure the efficacy of prescribed drug treatments (1 in 100 people in developed countries) ° Adjunct to blood tests in the diagnosis of Hereditary Haemochromatosis (HHC) or to rule out ir
Slide 8: Liver Biopsy is the Current Gold Standard for Measuring Liver Iron
Liver Biopsy is the Current “Gold Standard” for Measuring Liver Iron A tny Incision is made between the ribs and aneedieds ingerted in-arder te reach the area of the liver where a lisse Sample ts taken. The procedure requires a local anesthesia. Arga where a tigen ; sample is taken from Blogsy If an
Slide 9: Ferriscan Has The Potential To Reduce Cost & Improve Patient Care
Ferriscan™ Has The Potential To Reduce Cost & Improve Patient Care Reduced cost of care: Improve patient monitoring and safety Only a liver biopsy provides information on possible contributions of iron to the progression of iron overload diseases however, an estimated 60% of patients refuse liver bi
Slide 10: The Ferriscan Test Process Leverages Existing MRI Infrastructure
The Ferriscan™ Test Process Leverages Existing MRI Infrastructure MRA image ivO's Centatinage Avaly sia Contre *Utilizes existing MRI scanners with no new equipment purchases *MRI images processed off-line at a central centre, using IVB proprietary software, optimising quality control and security o
Slide 11: Ferriscan offers significant benefits over the gold standard alternative
W Ferriscan™ offers significant benefits over the “gold standard” alternative for iron level tests FerriScan™ 1. 2. Non-invasive and painless Can be performed regularly if necessary No hospital stay Can be performed on infants and young children . Cheaper and more efficient to administer Reduced lia
Slide 12: Available Globally - Processed Locally
Available Globally - Processed Locally 12 MRI units can be enabled remotely to incorporate th Technology and to perform the FerriScan™ Test Liver Scans from the MRI (off-line) are sent via the Internet to the | FerriScan™ Analysis Service Centre in Perth, Western Australia FerriScan’s proprietary so
Slide 13: Ferriscan / Iron Overload Application: USA & Australian Market Potential
13 Ferriscan™ / Iron Overload Application USA & Australian Market Potential Australia Total Market: genetic 125,000 predisposition for iron overload Addressable Market: Clinically aan : 33,000 * 750,000 significant iron overload : : ™ . Potential FerriScan™ service fee $250 - $350 $250 - $450 (AUD)
Slide 14: Growth in Current Diagnostic Tests for Iron Overload
Growth in Current Diagnostic Tests for lron Overload Over a five-year consecutive” period (1999-2003) financial years), the volume of blood iron studies performed increased by 92%, gene tests specific for haemochromatosis increased by 31% and needle liver biopsies increased by 38%. Source: Medicare
Slide 15: Ferriscan Indicative Model of Potential Gross Profit
Ferriscan™ Indicative Model of Potential Gross Profit Based on %US / Aus Potential Revenue * | Test Numbers Addressable Market 65% GM GM 20,000 2.5% $6M _| $3.9M 40,000 5% $12M $7.8M 60,000 7.5% $18M $11.7M 100,000 2 12.5% $30M $19.5M Note: ' At average revenue of AUD$300 per test 2 <4 scans / week
Slide 16: Ferriscan unites strong margins, short-time to market and a novel diagnostic service
16 Ferriscan unites strong margins, short-time to market and a novel diagnostic service Medical Devices European Diagnostic: Innogenetics; BioPredictive Australian Device: Sirtex Australian: CompuMedics; ResMed USA: MedicSight; Vital Images; Viatronix Health Services Australian: DCA; Sonic Healthcar
Slide 17: Benchmark examples of Diagnostic Imaging companies
7 Benchmark examples of Diagnostic Imaging companies vice —y Medical _ Diagnostic Service Company Description Mkt Cap: Cash: MedicSight Medicsight is a medical imaging software company. Its core Mc: US$165m FDA approvals for three products (USA) technology is focused on developing automatic detectio
Slide 18: Board of Directors - Resonance Health
Board of Directors - Resonance Health * Hon. Dr Michael Wooldridge. (Non-Executive — Former Australian Federal Minister for-Health ° Mr Tony Fitzgerald (Executive Director) —- Legal and healthcare licensing expertise, 18 years experience in commercialising healthcare and biotech projects ; - Ghairma
Slide 19: New Operational Management
New Operational Management 19 Dr James Williams BSc (Hons) F PhD MBA, CEO (appointed Ma’ ~ Prior roles include CEO, implantable medical device product with regulatory appro under 2 years, successful surgeon accreditation program and reimbursement prograi ~ Co-founder and non-exec Director of Tessitu
Slide 20: RHT Pro-forma capital structure
20 RHT Pro-form capital structure Assumes 100% ownership of IVB (As at 31 March 2005) Shares on issue: Currently on issue and listed (RHT) Proposed issue of ordinary shares to IVB shareholders Outstanding performance shares ~ 13,000,000 Total shares on issue — all classes : 192,494,023 Market Capita
Slide 21: Major Progress Towards Commercialisation of Ferriscan
Major Progress Towards Commercialisation of Ferriscan™ 21 TGA listing achieved in Australia — December 20 European marketing approval — CE Mark achieved, January 2005 US FDA 510(k) clearance received January 2005 DCA Group (Australia’s largest diagnostic imaging group) confirmed as partner for initi
Slide 22: Forward looking statements and risks
This presentation contains forward-looking statements t at are 22 Forward looking statements and risks management's current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the healthcare technology
Slide 23: Contact Details
23 Contact Details Tony Fitzgerald, Executive Director Resonance Health Ltd ABN 96 006 762 492 Ground Floor, 117 Stirling Highway, NEDLANDS Western Australia 6009 Tel +61 8 93895933 Fax +61 8 9389 5944 dames Williams, CEO Inner Vision Biometrics Pty Lid ABN 11 092 813 244 First Floor, 216 Stirling H
Resonance Health — Investor Presentation (April 2005) on 6ix